N-(2-pyridylmethylene)methylamine | 7032-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(2-pyridylmethylene)methylamine
• 英文别名: 2-Methyliminomethyl-pyridin
• CAS: 7032-20-4；40468-83-5
• 化学式: C₇H₈N₂
• 分子量: 120.154
• InChiKey: RKBLQRJXXOWNDA-VURMDHGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.13
• 重原子数：
  9.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.25
• 氢给体数：
  0.0
• 氢受体数：
  2.0

文献信息

• Bio-orthogonal drug activation
  申请人：TAGWORKS PHARMACEUTICALS B.V.

  公开号：US10967069B2

  公开（公告）日：2021-04-06

  The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.

  本发明涉及一种用于治疗的原药活化方法，其中使用了相互之间具有生物正交反应性的非生物活性化学基团。本发明还涉及一种原药试剂盒，包括至少一种原药和至少一种活化剂，其中原药包括药物和第一生物正交反应基团（触发器），活化剂包括第二生物正交反应基团。本发明还涉及上述方法和试剂盒中使用的靶向治疗药物。本发明尤其涉及抗体-药物共轭物以及双特异性和三特异性抗体衍生物。
• PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP3192511B1

  公开（公告）日：2021-07-14
• BIO-ORTHOGONAL DRUG ACTIVATION
  申请人：TAGWORKS PHARMACEUTICALS B.V.

  公开号：US20190336612A1

  公开（公告）日：2019-11-07

  The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
• [EN] UNIMOLECULAR LIGAND-INITIATOR DUAL FUNCTIONAL SYSTEMS (UMLIDFS) AND USE THEREOF<br/>[FR] SYSTÈMES BIFONCTIONNELS LIGAND - INITIATEUR UNIMOLÉCULAIRES (UMLIDFS) ET LEUR UTILISATION
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2011040881A1

  公开（公告）日：2011-04-07

  This invention relates to the polymerization of vinyl monomers by atom transfer radical polymerization (ATRP) using metal salts in ppm molar quantities. It relates to the polymerization under ATRP conditions using unimolecular ligand-initiator dual functional systems (UMLIDFS) where the initiator and ligand for complexing the metal are part of the same molecule.
• [EN] HEAT-SENSITIVE COPOLYMERS CAPABLE OF COMPLEXING CO(II) CATIONS IN AN AQUEOUS SOLUTION<br/>[FR] COPOLYMERES THERMOSENSIBLES APTES A COMPLEXER LES CATIONS DE Co(II) EN SOLUTION AQUEUSE
  申请人：ONET TECH ND

  公开号：WO2019077223A1

  公开（公告）日：2019-04-25

  La présente invention concerne des copolymères thermosensibles capables de complexer des cations divalents de Cobalt en solution aqueuse et leur utilisation pour le traitement d'un milieu aqueux liquide d'effluent chargé en cobalt Co(II) par microfiltration des floculats de complexes obtenus par élévation de température au-dessus de la température de point de trouble.